RegenxBio makes partnering splash, adds AbbVie for AMD gene therapy

After years of partnering out its AAV vector platform, RegenxBio has attracted AbbVie to the first deal from its internal gene therapy pipeline.

RegenxBio Inc. (NASDAQ:RGNX) granted AbbVie Inc. (NYSE:ABBV) exclusive rights to develop and commercialize ophthalmology gene therapy RGX-314. The AAV8 vector that expresses a mAb fragment that binds VEGF is in Phase III testing to treat wet AMD and Phase II testing to treat diabetic retinopathy. ...